{"id":"hum0163","secondaryIds":[],"version":2,"url":"https://humandbs.dbcls.jp/research/hum0163/v2","datePublished":"2021-02-09","versions":[{"version":1,"datePublished":"2018-12-14"},{"version":2,"datePublished":"2021-02-09"},{"version":3,"datePublished":"2023-04-21"}],"title":{"ja":"精神・神経疾患治療薬及びがん治療薬におけるファーマコゲノミクス研究","en":"Pharmacogenomics research for therapeutics in psychiatry, neurology and oncology"},"summary":{"aims":{"ja":"精神・神経疾患及びがん治療における薬効・副作用に関連する遺伝子・代謝産物（バイオマーカー）を同定し、将来の、ゲノム情報に基づいた層別化医療（stratified medicine）の実現の足がかりとする。","en":"Identification of biomarkers associated with efficacy and adverse drug reactions in therapeutics for psychiatric/neurological disorders or cancers, leading to establishment of stratified medicine based on pharmacogenomic information."},"methods":{"ja":"精神・神経疾患及びがん患者を対象に、DNA、血漿及びカルテ情報を収集する。薬物動態に関連する100遺伝子（Pharmacogene）を対象としたターゲット・リシークエンス解析やヒト白血球抗原（Human Leukocyte Antigen：HLA）タイピング等のゲノム解析、メタボローム解析、ファーマコカイネティクス解析により、薬剤応答性関連遺伝子・代謝産物（バイオマーカー）を探索する。","en":"DNA/plasma samples and clinical information are collected from patients with psychiatric/neurological disorders or cancers. Targeted NGS analysis focusing on 100 pharmacogenes, HLA typing, metabolome analysis, and pharmacokinetic analysis were conducted to identify biomarkers associated with drug responses."},"targets":{"ja":"ラモトリギン、クロザピンなどの向精神薬による治療症例、レゴラフェニブ、トラスツズマブ、ニボルマブなどのがん分子標的治療薬による治療症例、抗てんかん薬による治療症例","en":"Patients receiving psychotropic drugs (lamotrigine and clozapine), and patients receiving anti-cancer molecular targeted drugs (regorafenib, trastuzumab and nivolumab)"},"url":{"ja":[{"url":"https://www.amed.go.jp/koubo/04/01/0401C_00078.html","text":"https://www.amed.go.jp/koubo/04/01/0401C_00078.html"}],"en":null}},"listingSummary":{},"releaseNote":{"en":"Genotype frequencies of NAT2 identified from the targeted capture sequencing (NGS) analysis were provided (csv file)."},"dataProviders":[{"name":{"ja":"莚田 泰誠","en":"Taisei Mushiroda"},"organization":{"name":{"ja":"理化学研究所 生命医科学研究センター ファーマコゲノミクス研究チーム","en":"RIKEN Center for Integrative Medical Sciences, Laboratory for Pharmacogenomics"}}}],"researchProjects":[],"grants":[{"title":{"ja":"精神・神経疾患治療薬及びがん治療薬におけるファーマコゲノミクス研究","en":"Pharmacogenomics research for therapeutics in psychiatry, neurology and oncology"},"agency":{"ja":"日本医療研究開発機構 ゲノム医療実現推進プラットフォーム事業（先端ゲノム研究開発）","en":"Advanced Genome Research and Bioinformatics Study to Facilitate Medical Innovation (GRIFIN), Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED)"},"grantIds":["JP16km0405201"]}],"relatedPublications":[{"title":"GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.","doi":"https://doi.org/10.18632/oncotarget.25712","datasets":["NHA000076"]}],"datasets":["NHA000076","NHA000159"],"controlledAccessUsers":[]}